
Cardiovascular Outcome Trial Update in Diabetes: New Evidence, Remaining Questions.
PURPOSE OF REVIEW: Seven trials of new agents to treat type 2 diabetes (T2DM) have been performed to assess cardiovascular (CV) safety. A significant amount of information regarding the effects of drugs in three classes is available, with new data from multiple other trials expected shortly. This article provides a summary of recently completed trials. RECENT FINDINGS: The dipeptidyl peptidase-4 inhibitors studied thus far do not alter the risk of major adverse CV events (MACE). Glucagon like peptide-1 receptor agonists liraglutide and semaglutide, and the sodium glucose cotransporter-2 inhibitor empagliflozin, significantly reduced the risk of MACE. Empagliflozin also decreased the risk of hospitalization for heart failure. Agents demonstrating a CV outcome benefit also improved parameters of renal function. Several newer antihyperglycemic agents have been found to reduce the risk of important CV complications in high-risk patients with T2DM. Future trials are needed to assess the effects of additional drugs and the impact of therapy in lower risk patients and provide additional information regarding non-CV safety outcomes.
Duke Scholars
Altmetric Attention Stats
Dimensions Citation Stats
Published In
DOI
EISSN
Publication Date
Volume
Issue
Start / End Page
Location
Related Subject Headings
- Risk Factors
- Hypoglycemic Agents
- Hyperglycemia
- Humans
- Endocrinology & Metabolism
- Diabetes Mellitus, Type 2
- Clinical Trials as Topic
- Cardiovascular Diseases
- 3210 Nutrition and dietetics
- 3202 Clinical sciences
Citation

Published In
DOI
EISSN
Publication Date
Volume
Issue
Start / End Page
Location
Related Subject Headings
- Risk Factors
- Hypoglycemic Agents
- Hyperglycemia
- Humans
- Endocrinology & Metabolism
- Diabetes Mellitus, Type 2
- Clinical Trials as Topic
- Cardiovascular Diseases
- 3210 Nutrition and dietetics
- 3202 Clinical sciences